Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
With
Canadian Association of Radiation Oncology
AbbVie
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age 18 or older
Study Informed Consent provided
Pathologically proven diagnosis of prostatic adenocarcinoma
Unfavorable intermediate risk \[with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate\] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification \[Prostatic Specific Antigen (PSA) \> 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10\]
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy
You may not be if
Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
Plan for adjuvant docetaxel post-radiotherapy
Serious medical comorbidities or other contraindications to HDR-BT
